Sun Pharmaceutical Industries Ltd. on Monday said it has elevated Aalok Shanghvi as Chief Operating Officer.
He is currently designated as Whole-time Director and Executive Vice-President, Emerging Markets, Global Generic R&D, Global Business Development (Generics), Operations and API.
Shanghvi, son of Sun Pharma Managing Director Dilip Shanghvi, joined Sun Pharma in 2006 and has handled various roles in marketing, R&D, project management, purchase and communications, the Mumbai-based drug major said in a regulatory filing.
In 2014, he became the Head of Emerging Markets business, spread across 80 countries covering Africa, the Middle East, APAC, Eastern Europe, CIS, and Latam.
RECOMMENDED FOR YOU

Stock Picks Today: Sun Pharma, KPIT Tech, BHEL, Nazara Tech, CMS Info, Godrej Properties On Brokerages' Radar


Trump Tariffs: Bitter Pill For Sun Pharma? Goldman Sachs Explains Why The Drugmaker May Face Pressure


US Tariffs: Only Sun Pharma Exposed To Some Headline Risk, But With Limited Earnings Impact


Trump Tariffs May Not Hurt Indian Companies, Says Morgan Stanley: THIS Pharma Stock An Exception
